Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study

Rupp U, Sohn C, Sinn H, Huober J, Hanft G, Staab A, Schmidt P, Lauschner I, Schuetz F, Eichbaum M, Schoendorf-Holland E, Schneeweiss A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-cancer drugs 2007; 18:477-85.